Objective: To establish the ecacy of Macroplastique 1 in treating vesico-ureteric re¯ux (VUR) in adults with neuropathic bladder dysfunction. Patients and methods: Fifteen patients (12 male and three female), age range 19 to 80 years (mean age 38) were included in this study. Diagnosis was con®rmed by videourodynamics. In seven patients re¯ux was present bilaterally. Twenty-two re¯uxing ureters were treated. Twelve patients had detrusor hyper-re¯exia, two had are¯exic bladders and one had loss of bladder wall compliance. According to the International Grading System, 10 ureters had grade IV re¯ux, ®ve had grade III re¯ux, ®ve had grade II re¯ux, and two had grade I re¯ux. Macroplastique 1 (0.5 ± 1.5 ml) was injected submucosally under each ureteric ori®ce to convert the opening to a slit like shape. The patients were followed up from 9 to 68 months. Results: VUR was completely resolved in 72.7% (16) ureters following a single injection and in a further 4.5% (1) ureter following a second injection. 9.1% (2) ureters were improved and treatment failed in 13.7% (3) ureters. Two patients showed a recurrence of re¯ux 1 and 4 years after primary injection and subsequently had a curative second injection. Most of the patients in whom VUR was cured or improved showed a reduction in laboratory proven urinary infection rates. Conclusion: Macroplastique 1 produced an excellent result (86% with complete resolution or improvement of re¯ux) in treating VUR in adult neuropathic bladders. This is comparable to larger studies carried out on the paediatric population. This is an easy procedure, which avoids major surgery and can be performed as a day case. In cases of failure or recurrence, repeat injection or open surgery can be undertaken without any added complications. Spinal Cord (2001) 39, 92 ± 96
Introduction
Vesico-ureteric re¯ux (VUR) is a major cause of morbidity in patients with neuropathic bladder dysfunction. 1 If left untreated it may result in hydronephrosis and ascending urinary tract infection (UTI), resulting in progressive renal deterioration, 2 which may ®nally lead to renal failure.
Whilst open surgical anti-re¯ux procedures are eective in correcting re¯ux, they are not free from complications even in the best hands. Furthermore, these procedures are more dicult in thick walled trabeculated neuropathic bladders often with less rewarding results as compared to correction of primary VUR. 3, 4 Correction of VUR by endoscopic injection of Te¯on paste was ®rst described by Matovschek in 1981. 5 Since then, numerous investigators have reported encouraging results of endoscopic correction of both primary and secondary VUR mostly in children. 6 ± 12 Little experience is reported in adults with neuropathic bladder dysfunction. Foley et al 13 previously reported our unit's treatment of a small series of secondary VUR in adults with neuropathic bladders. Here we report on a large series of patients with neuropathic bladder dysfunction undergoing endoscopic injection of Macroplastique 1 (Uroplasty BV, Maastricht, The Netherlands) to treat VUR. Macroplastique 1 implants are sterile, nonpyogenic, solid textured polydimethylsiloxane particles suspended in a hydrogel carrier. Upon implantation, the hydrogel is substituted by body¯uids. Host ®broblasts subsequently deposit collagen around the Macroplastique 1 particles, which hold them in place. The hydrogel is later removed by the reticuloendothelial system and excreted unmetabolised through the kidneys.
Patients and methods
Twenty-two re¯uxing ureters in 15 patients (12 male and three female), aged between 19 and 80 years (median age 38 years) were treated by Macroplastique 1 injection between 1993 and 1998 (Table 1) . Neuropathic bladder dysfunction was secondary to spinal cord injury in 13 patients, spina bi®da in one patient and following surgical removal of a sacral sarcoma in one patient (patient 13). Twelve patients had detrusor hyper-re¯exia (DH), two had are¯exic bladders and one had loss of bladder wall compliance (LOC). All patients with DH were on oxybutynin except those on condom drainage relying on DH for bladder emptying (patients 7, 9, 11) and patient 5 who had a SARSI (Sacral Anterior Root Stimulator Implant). The latter four patients did not wish to take oxybutynin and thus alter their preferred bladder management. Despite a maximum daily dose of oxybutynin, patient 14 had persistent high pressure DH. The rest of the patients on oxybutynin had well suppressed detrusor pressures. Preoperative assessment included documentation of current bladder management and frequency of UTI.
VUR was con®rmed and graded as per the International Grading System 14 by videourodynamics (VCMG) in every patient. In seven patients re¯ux was present bilaterally. According to the International Grading System, 10 ureters had grade IV re¯ux, ®ve had grade III re¯ux, ®ve had grade II re¯ux, and two had grade I re¯ux. Patients 7, 9 and 11 on condom drainage, patient 5 with SARSI and patient 14 with poorly controlled DH on oxybutynin had high pressure (430 cmH 2 O) VUR. The remainder of the patients had low pressure (520 cmH 2 O) VUR.
Patients with symptomatic UTI or bladder stones had these treated prior to Macroplastique 1 injection. The procedure was usually performed as a Day Case. Patients were treated under general anaesthesia to reduce the diculty with autonomic dysre¯exia and received an intravenous antibiotic (gentamicin 80 mg) at induction. Using an aseptic technique the lumen of the endoscopic needle, pre-lubricated with E-Z Gel TM and attached to a Macroplastique 1 syringe, was primed. The needle was passed down the instrument channel of a Miller cytoscope. Under direct vision the mucosa was punctured approximately 0.5 cm below the ureteric ori®ce and the needle was advanced submucosally approximately 0.5 ± 1.0 cm until the needle tip was directly underneath the ureteric ori®ce. Slowly the Macroplastique 1 (0.5 ± 1.5 ml) was injected under the ureter until a volcano-like appearance is achieved, resulting in a crescent-shaped ureteric opening ( Figure 1 ). Both ureters were injected at the same time in bilateral cases.
Patients were followed up at 3 months and thereafter at least annually. The frequency of laboratory proven urinary tract infections requiring antibiotic treatment was recorded at each follow-up from infection diaries. VCMG and an upper urinary tract ultrasound scan were routinely performed postoperatively at 3 months and thereafter at least every 2 years. The results were graded as Cured, Improved (downgrading of re¯ux) and Failed. Repeat injections were given in cases of failure and recurrence. Open surgical intervention was reserved for those who failed to show any improvement.
Results
No patients developed postoperative UTI or ureteric obstruction as a result of the procedure. The identi®cation of the ureteric ori®ce was dicult in Table 2 , with overall results shown in Table 3 .
. Both these patients had small capacity (less than 150 ml), grossly trabeculated, thick walled bladders that were drained by suprapubic catheter (SPC) on free drainage. Furthermore, patient 15 had recurrent problems of bladder stone formation. 1  IV  IV  0  III  36  0  12  2  II  IV  II  IV  24  Awaiting  Awaiting  3  III  III  0  0  18  4  I  I  0  0  1 2  5  III  0  12  6  I V  I I  0  0  4 8  7  IV  II  III  0  42  8  I V  0  5 6  9  I V  0  4 8  10  II  0  12  11  III  0  10  12  IV  0  21  13  III  0  9  14  II  IV  I  0  68  15  IV  IV  12 Awaiting Vesico-ureteric reflux N Shah et al Eight patients (Table 1) had pre-operative recurrent laboratory proven UTI (at least once every 2 months requiring antibiotic treatment). All but two patients (7 and 15) experienced a reduction in the frequency of laboratory proven infections post-operatively. Due to poorly controlled high intravesical pressures in patient 14, a clam-ileocystoplasty was performed with reimplantation of the right ureter in which there was persisting low grade (I) re¯ux post Macroplastique 1 injection. This cured the residual re¯ux.
Discussion
Subureteric injection for the correction of VUR was ®rst described in piglets using PTFE (Te¯on) in 1984 by Puri and O'Donnell. 15 Since then there has been 15 years of experience in treating VUR, mainly in children, and in excess of 30 years in the treatment of urinary incontinence using PTFE. 8 Overall results with PTFE from a European survey have been impressive with 84.9% of re¯uxing ureters being cured and a further 10.2% improving following up to two injections. 16 Concerns have been raised of the possibility of migration and granulomatous reaction following periurethral Te¯on injection 17 and some anecdotal reports of potential carcinogenesis in humans with Te¯on. 18, 19 However, the risk of migration is limited with the small quantity (50.3 ml) of Te¯on used for subureteric injection. For the cases of carcinogenesis reported with Te¯on, there has not been a de®nite causal relationship. 8 Other injectables used for treating re¯ux include collagen and Macroplastique 1 . No randomised controlled trial exists to compare the ecacy of these dierent injectables. A retrospective review of a 7-year experience by Dodat et al 20 reported some superiority of Macroplastique 1 over Te¯on (93.3% vs 85.7% resolution of VUR after one or two injections) and collagen (52.6% resolution of VUR). Furthermore, the failure rate was least with Macroplastique 1 (11.8%) compared to Te¯on (16.7%) or collagen (52.6%). The failure with collagen being related to resorption, whilst that with Te¯on being due to lateralisation and secondary elimination of the product from the injection site due to its¯uidity. Macroplastique 1 was claimed to be superior due to its higher viscosity and absence of retraction.
Concern about safety of silicone has arisen from published reports showing an association between silicone-gel breast implant and connective tissue disorders. 21 ± 23 But these complications were related to the liquid form of silicone, which had leaked from the implant. 24 Macroplastique 1 is an elastomer composed of solid particles and is more inert than silicone gel, causing a mild acute in¯ammatory reaction that decreases 2 ± 4 weeks after injection. 25 There is no convincing evidence that such elastomers are associated with connective tissue disease. 26 In our experience endoscopic injection of Macroplastique 1 produced an excellent result (77% with complete resolution and a further 9% with downgrading of re¯ux) in treating VUR in adult neuropathic bladders. This is comparable to larger studies carried out on the paediatric population. 8, 20 None of our patients developed vesico-ureteric obstruction following the injection. The incidence of the latter is low and usually temporary and is best managed by temporary stenting.
The two failures reported (patient 2 and 15) were both in patients with SPC in small capacity, trabeculated, thick walled bladders further complicated by recurrent bladder stones in patient 15. Furthermore, Macroplastique 1 injection was dicult to perform in both these patients due to their bladder wall characteristics. Interestingly, of the 15 patients, six had a SPC in situ for bladder drainage. Two of these six patients had an are¯exic bladder on VCMG. The reason for the occurrence of VUR in patients with SPC is not entirely clear, perhaps the catheter tip/ balloon irritates the trigone region thus altering the dynamics of the vesico-urethral junction.
Renal deterioration in spinal cord injured patients with VUR is well documented. 2 Indeed three of the patients treated had demonstrable renal deterioration aecting the side with higher grade re¯ux prior to the Macroplastique 1 injection. Despite curing the re¯ux in one of these patients (patient 6), the renal function failed to improve on follow-up isotope renal study. However, we feel that treating VUR should prevent further deterioration in renal function.
Long term follow-up is necessary in this group of patients as delayed recurrence of VUR was noted in two patients (5 and 6). In both these cases repeat injection of Macroplastique 1 was curative. Unlike the paediatric population spontaneous resolution of VUR is not expected in adults with secondary re¯ux. Initial management of VUR secondary to a high pressure neuropathic bladder should be aimed at lowering the intravesical pressures using anticholinergic medication. Intervention is deemed necessary for persisting VUR despite low intravesical pressures and was the case for most of our patients. Patients 7, 9, and 11 wished to continue with condom drainage, hence anticholinergics were considered inappropriate, as was also the case with patient 5 with a sacral root stimulator.
The success rate of open surgical correction of secondary VUR in thickened trabeculated neuropathic bladders is not as good as for re¯ux in nonneuropathic bladders. 3, 4 Furthermore open surgical procedures further stress already distressed patients with spinal injury. Endoscopic injection of Macroplastique 1 is simple, eective and without complications, and can be performed as a day case procedure. Open surgical correction is not complicated by a prior injection of Macroplastique 1 and should be reserved for patients who have persisting VUR following failed endoscopic correction.
This study shows that submucosal injection of Macroplastique 1 to be a simple and eective Vesico-ureteric reflux N Shah et al treatment in this dicult group of patients. We would recommend that endoscopic correction should be ®rst line surgical treatment option for the correction of VUR in adult neuropathic bladders.
